Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

Wu, Szu‐Yuan; Chen, Wan-Ming; Chen, Yi-Chan; Chiang, Ming-Feng; Lee, Ming-Che; Soong, Ruey-Shyang

doi:10.1016/j.diabet.2022.101393

Cited by 9 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hyperglycemia stimulates inflammation, and inflammatory cells secrete cytokines and chemokines that proliferate malignant cells, inhibit apoptosis, aid angiogenesis, and promote metastasis [32]. Therefore, AH use might modulate chronic inflammation and hyperglycemia in those with T2DM, thereby contributing to the reduction of HNC risk [33,34] this conclusion aligns with previous clinical studies [19,21]. The reason behind the protective role of AHs against HNC associated with diabetes is not clear, and several theories have been proposed.…”

Section: Discussionsupporting

confidence: 72%

“…An AH prescription was defined as previously reported in the protocol [19,21]. In this study, AHs were used for various conditions including asthma, allergic rhinitis, medication allergies, environmental allergies, or viral infections (such as itchy eyes, runny nose, and pruritus).…”

Section: Ah Usementioning

confidence: 99%

“…A retrospective cohort study from 2022 showed that AH use may decrease the risk of hepatocellular carcinoma in a dose-dependent manner among patients infected with hepatitis B virus, hepatitis C virus, or both [19]. Another study found that AH use can lower the risk of HCC in patients with T2DM who are not infected with hepatitis B or C, and the effect is dosedependent [21]. Despite a growing body of evidence on the anticancer properties of AHs [17][18][19][20][21], the impact of their use on HNC risk in patients with T2DM has not been fully explored.…”

Section: Introductionmentioning

confidence: 99%

“…Another study found that AH use can lower the risk of HCC in patients with T2DM who are not infected with hepatitis B or C, and the effect is dosedependent [21]. Despite a growing body of evidence on the anticancer properties of AHs [17][18][19][20][21], the impact of their use on HNC risk in patients with T2DM has not been fully explored. To fill this gap, we performed a nationwide, population-based cohort study using propensity score matching (PSM) to assess the association between AH use and HNC risk in T2DM patients.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus

CHEN¹,

CHEN²,

CHEN³

et al. 2023

Oncology Research

Self Cite

View full text Add to dashboard Cite

This study aimed to examine the association between the use of H1-antihistamines (AHs) and head and neck cancer (HNC) risk in patients with type 2 diabetes mellitus (T2DM). Data from the National Health Insurance Research Database of Taiwan were analyzed for the period from 2008 to 2018. A propensity-score-matched cohort of 54,384 patients each in the AH user and nonuser groups was created and analyzed using Kaplan-Meier method and Cox proportional hazards regression. The results showed that the risk of HNC was significantly lower in AH users (adjusted hazard ratio: 0.55, 95% CI: 0.48 to 0.64) and the incidence rate was also lower (5.16 vs. 8.10 per 100,000 person-years). The lower HNC incidence rate in AH users (95% CI: 0.63; 0.55 to 0.73) suggests that AH use may reduce the risk of HNC in T2DM patients.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Ah Usementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus

CHEN¹,

CHEN²,

CHEN³

et al. 2023

Oncology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…The NHIRD is a valuable resource for populationbased research as it contains comprehensive medical claims data for all National Health Insurance beneficiaries in Taiwan, including diagnoses, procedures, drug prescriptions, demographics, and enrollment profiles. [26][27][28][29][30][31] The data is encrypted using unique patient identifiers and is linked to the death registry and Taiwan cancer registry database, allowing for determination of vital status and cause of death for each included patient. 10,32,33 Additionally, the Health Promotion Administration of the Ministry of Health and Welfare in Taiwan implemented a program for oral cancer screening in 2004, which enabled us to identify high-risk individuals for oral cancer through their betel nut chewing habits by linking the National Oral Cancer Screening database with the NHIRD.…”

Section: Study Populationmentioning

confidence: 99%

The effect of statin medication on the incidence of oral squamous cell carcinoma among betel‐nut chewers

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background This study examines the relationship between statin use and oral cancer squamous cell carcinoma (OCSCC) risk in a cohort of 47 942 betel nut chewers. Methods The study used individual 1:1 matching and propensity score matching to compare statin users and nonusers. Results The incidence rate of OCSCC was significantly lower in statin users compared to nonusers (17.12 vs. 26.75 per 10 000 person‐years), yielding an incidence rate ratio of 0.64. After adjusting for confounders, statin use was associated with a reduced risk of OCSCC (adjusted hazard ratio: 0.61; 95% confidence interval: 0.52–0.71). A dose–response relationship was observed, with a significant reduction in OCSCC incidence when the cumulative defined daily dose of statin use was equal to or greater than Q3. The risk of OCSCC was lower among users of both hydrophilic and lipophilic statins. Conclusion This study provides evidence that statin use is associated with a reduced risk of OCSCC in betel nut chewers.

show abstract

Statin use and its association with decreased risk of esophageal squamous cell carcinoma in betel nut chewers

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundBetel nut chewing involves the chewing of areca nuts or betel quid (areca nuts wrapped in betel leaves), which is associated with an increased risk of esophageal squamous cell carcinoma (ESCC). Statins have anticancer properties. We investigated the association between statin use and ESCC risk in betel nut chewers.MethodsThe study included 105 387 betel nut chewers matched statin users and nonusers. Statin use was defined as the use of ≥28 cumulative defined daily doses (cDDDs) of statin. The primary outcome was incidence of ESCC.ResultsThe incidence rate of ESCC was significantly lower in statin users than in nonusers (2.03 vs. 3.02 per 100 000 person‐years). Statin users had a lower incidence rate ratio of 0.66 for ESCC (95% confidence interval [CI]: 0.43–0.85) relative to nonusers. After potential confounders were adjusted for, statin use was determined to be associated with a reduced risk of ESCC (adjusted hazard ratio [aHR], 0.68; 95% CI: 0.51–0.91). A dose–response relationship was observed between statin use and ESCC risk; the aHRs for statin use at 28–182 cDDDs, 183–488 cDDDs, 489–1043 cDDDs, and > 1043 cDDDs were 0.92, 0.89, 0.66, and 0.64, respectively.ConclusionStatin use was revealed to be associated with a reduced risk of ESCC in betel nut chewers.

show abstract

Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

Cited by 9 publications

References 38 publications

H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus

H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus

The effect of statin medication on the incidence of oral squamous cell carcinoma among betel‐nut chewers

Statin use and its association with decreased risk of esophageal squamous cell carcinoma in betel nut chewers

Contact Info

Product

Resources

About